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Introduction
Surveillance of antimicrobial consumption is a necessary
step to develop and monitor policies to limit antimicrobial
overuse/misuse and to decrease the risk of bacterial resis-
tance. In Saudi Arabia, such surveillance data are lacking.
Objectives
To quantify the carbapenems use in intensive care unit
(ICU) setting and to detect any variability by ICU type.
Methods
We conducted a prospective surveillance study in eight
different ICUs; five adult and three pediatric/neonatal
ICUs at King Abdulaziz Medical City, Riyadh, Saudi
Arabia, Riyadh, from October 2012 through December
2013. We estimated the consumption of carbapenems as
days of use (which was defined as the aggregate sum of
days for which any amount of meropenem or imipenem
were administered) per 1000 bed-days or 100 admissions.
Results
We recorded carbapenem use for more than 3500 bed-
days during 15 months in 8 ICUs having a total 131 bed
capacity. The overall carbapenem use was estimated at
133.7 days of use per 1000 bed-days and 150.8 days of
use per 100 admissions. The use per bed-days was high-
est in adult medical surgical ICU (357.0) followed by
adult step-down (232.4) and burn (195.4) ICUs but low-
est in neonatal ICU (27.7) and adult cardiothoracic ICU
(64.9). The use per admissions was highest in adult
step-down ICU (467.8) followed by burn (394.9) and
adult medical surgical (384.0) ICUs but lowest in adult
cardiothoracic (31.2) and pediatric medical-surgical
(58.9) ICUs.
Conclusion
Approximately, our ICU patients use carbapenems one-
eighth of the days spent. There is wide variability in carba-
penem use in different ICUs that warrant ICU-specific
reporting and pinpoint areas that need more management
attention. There is need to identify patient and physician
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